NBIX — Neurocrine Biosciences, Inc.

Neurocrine Biosciences (NBIX) Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Product Sales: $790 million, a 28% year-over-year increase.
• INGREZZA Sales: $687 million, marking a record with double-digit growth and strong new patient additions.
• CRENESSITY Sales: $98 million, reflecting strong early adoption with 80% of prescriptions reimbursed.
• Cash Position: Over $2.1 billion, with no debt.
• SG&A Expense Increase: Anticipated increase of approximately $150 million in 2026 due to sales force expansions.

2. Strategic Updates and Business Highlights

• Sales Force Expansion: Plans to expand the sales force for both INGREZZA and CRENESSITY to enhance market penetration and patient access.
• Clinical Pipeline: Progress in Phase III studies for osavampator (major depressive disorder) and direclidine (schizophrenia). Initiation of 4 new Phase I studies and 2 Phase II studies expected.
• CRENESSITY Launch: Positioned as a first-in-class therapy for congenital adrenal hyperplasia (CAH), with ongoing efforts to establish it as the standard of care.
• Market Opportunity: INGREZZA continues to target the tardive dyskinesia (TD) market, with only 10% of diagnosed patients currently treated.

3. Forward Guidance and Outlook

• Q4 Expectations: Anticipated sequential growth of $15 million to $20 million, adjusting for a 14-week ordering dynamic in Q3.
• Long-term Growth: Confidence in sustained growth driven by strong market demand and strategic investments in sales and R&D.
• 2026 Projections: Continued strong performance expected, with a focus on maximizing patient share before the potential impacts of the Inflation Reduction Act (IRA).

4. Bad News, Challenges, or Points of Concern

• DOJ Investigation: Ongoing investigation regarding sales and marketing practices for INGREZZA, with Neurocrine cooperating fully.
• IRA Impacts: Concerns about potential pricing pressures and market dynamics as competitors navigate the IRA, although INGREZZA's patient retention is expected to mitigate some risks.
• Seasonality in CRENESSITY: Questions raised about potential seasonal impacts on new patient starts, though management indicated no significant seasonality expected.

5. Notable Q&A Insights

• CRENESSITY Adoption: Q3 saw 540 new patient starts, with management optimistic about continued growth despite a slight decline from Q2.
• Reimbursement Dynamics: Strong reimbursement rates for CRENESSITY, with 90% of patients receiving approval, alleviating initial concerns about access.
• Sales Force Strategy: The integration of psychiatry and neurology teams aims to streamline efforts and capitalize on growth opportunities in both segments.
• Market Share Insights: Neurocrine is gaining a majority of new patient starts in the VMAT2 market, indicating strong competitive positioning against AUSTEDO.

Overall, Neurocrine Biosciences reported a robust Q3 2025 performance, driven by strong sales growth and strategic initiatives, while also navigating challenges related to regulatory scrutiny and market dynamics.